CCM
IMVT icon

Camber Capital Management’s Immunovant IMVT Stock Holding History

Camber Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-438,800
Closed -$15.4M – 36
2020
Q3 		$15.4M Sell
438,800
-361,200
-45% -$10.9M 0.81% 29
2020
Q2 		$19.5M Buy
+800,000
New +$17.1M 1.11% 24

Other funds holding IMVT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Camber Capital Management's IMVT Position: Q4 2020 in Review

Camber Capital Management sold out of Immunovant (IMVT) in Q4 2020, closing a stake of 438,800 shares — an estimated $15.4M sold.

Camber Capital Management first reported a position in IMVT in Q2 2020 and held it in 2 quarters. The position peaked at $19.5M in Q2 2020. 147 funds tracked by Wall St. Rank hold IMVT as of Q4 2020.

  • Camber Capital Management reported no remaining Immunovant position as of Q4 2020 after selling out during the quarter.
  • Camber Capital Management sold 438,800 Immunovant shares in Q4 2020, an estimated $15.4M.
  • Camber Capital Management first reported a position in Immunovant in Q2 2020 and held it in 2 quarters.
  • Camber Capital Management's Immunovant position peaked at $19.5M in Q2 2020.
  • 147 funds tracked by Wall St. Rank held Immunovant as of Q4 2020.

Based on Camber Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.